Caption Management, LLC Ascendis Pharma A/S Put Options Transaction History

Caption Management, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $610,200 - $828,522	5,400 Added 76.06%	12,500 $1.87 Million
Q2 2024 Aug 14, 2024	SELL	$121.07 - $153.67 $5.19 Million - $6.59 Million	-42,900 Reduced 85.8%	7,100 $968,000
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $6.17 Million - $7.97 Million	50,000 New	50,000 $7.56 Million
Q2 2023 Aug 14, 2023	BUY	$69.96 - $97.84 $524,700 - $733,800	7,500 Added 30.0%	32,500 $2.9 Million
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $298,260 - $395,910	3,000 Added 13.64%	25,000 $3.05 Million
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $1.85 Million - $2.43 Million	22,000 New	22,000 $2.27 Million
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $1.95 Million - $2.94 Million	-25,000 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$102.18 - $135.75 $510,900 - $678,750	5,000 Added 25.0%	25,000 $2.93 Million
Q3 2021 Nov 12, 2021	SELL	$112.67 - $176.92 $16.9 Million - $26.6 Million	-150,300 Reduced 88.26%	20,000 $3.19 Million
Q2 2021 Aug 16, 2021	BUY	$121.62 - $145.29 $16 Million - $19.1 Million	131,500 Added 338.92%	170,300 $22.4 Million
Q1 2021 May 17, 2021	BUY	$124.92 - $173.33 $4.85 Million - $6.73 Million	38,800 New	38,800 $5 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.